10x Genomics develops instruments, consumables, and software for single-cell and spatial biology, enabling researchers to analyze gene expression and tissue at the cellular level.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Paul Tudor Jones / Tudor | 61 | New buy | 2,500 | $225,900 | 0.0% |
| Bridgewater | 55 | Added +771% | 116,482 | $10,525,314 | 0.0% |
| Steve Cohen / Point72 | 75 | Trimmed -96% | 74,611 | $6,741,850 | 0.0% |
| Report | Date | Stance |
|---|---|---|
| #135 — State of the Themes: The End of the Trade (As We Know It) | 2026-11-04 | WATCH |
| #134 — Citrini Therapeutics: We Wanted to Use Claude to Create a New Drug | 2026-10-20 | WATCH |
| #97 — Rough Seas Make Strong Sailors: Navigating the Healthcare Policy Tsunami | 2025-05-28 | WATCH |
| #92 — Market Memo: Talk to Me, Goose | 2025-04-13 | SHORT |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.